Biostax Corp.

Equities

BTAX

US45252A3059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:09 20/06/2024 pm IST			5-day change	1st Jan Change
0.0335 ^USD	-4.29%		-4.29%	-54.11%

20/05	Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 21, 2024 at 12:28 am IST

Biostax Corp. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 0.337076 million compared to USD 0.416117 million a year ago.

Latest news about Biostax Corp.

Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
Biostax Corp. Appoints Craig Suro as a Director	15/11	CI
Biostax Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Biostax Corp. Appoints Mary Clay Caperton to its Board of Directors	02/11	CI
Immune Therapeutics, Inc. will Change its Name to Biostax Corp	05/23/05	CI
Immune Therapeutics, Inc. Announces CEO Changes	14/23/14	CI
Immune Therapeutics, Inc. Announces Management Changes	14/23/14	CI
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	29/23/29	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18	CI
Immune Therapeutics, Inc. Announces the Fdas Acceptance of Three Investigational New Drug Applications Transfers for Jkb-122 for the Treatment of Nash, Nafld and Aih	15/23/15	CI
Biostax Corp. announced that it expects to receive $12 million in funding from DealBox, Inc	30/23/30	CI
DealBox, Inc announced that it has received $12 million in funding from Immune Therapeutics, Inc.	30/23/30	CI
Immune Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	10/23/10	CI
Immune Therapeutics, Inc. Announces Director Resignations	04/23/04	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Immune Therapeutics, Inc. Announces Executive Changes	10/22/10	CI
Immune Therapeutics, Inc. Announces CEO Changes	10/22/10	CI
Immune Therapeutics, Inc. Appoints H. Louis Salomonksy to Its Board of Directors	28/22/28	CI
Immune Therapeutics, Inc. announced a financing transaction	31/22/31	CI
Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
Immune Therapeutics, Inc. Announces the Appointment of Glen Farmer as Chief Financial Officer	04/22/04	CI
Immune Therapeutics, Inc. Announces the Appointment of Kelly O’Brien Wilson as Chief Operating Officer	04/22/04	CI

Chart Biostax Corp.

Duration

Period

More charts

Company Profile

Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOSTAX CORP.	-54.11%	2.8M
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
ARGENX SE	+8.24%	23.61B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-16.19%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B

Bio Therapeutic Drugs